Clinical Trial

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

Study acronym: DM OPF ROXY
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.
Trial Details
NCT Number NCT07536516
Lead Sponsor Medical University of Vienna
Conditions Diabetes Mellitus
Enrollment 20 participants
Start Date 2025-11-28
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-17